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NEWS & VIEWS
Does Oxidative Inactivation of CD45 Phosphatase
in Rheumatoid Arthritis Underlie
Immune Hyporesponsiveness?
David A. Rider, Rachel Bayley, Elizabeth Clay, and Stephen P. Young
Abstract
The protein tyrosine phosphatase (PTP) CD45 is critical in regulating the earliest steps in T-cell-receptor signaling
but, similar to all PTPs, it is susceptible to oxidative inactivation. Given the widely reported effects of oxidant
damage associated with rheumatoid arthritis (RA), we examined whether CD45 phosphatase activity was altered
in CD4+ T cells from RA patients and related this to CD4+ T-cell function and redox status. CD45 phosphatase
specific activity in T cells from RA peripheral blood (PB) and synovial fluid was 56% and 59% lower than in
healthy control (HC) PB, respectively. In contrast, CD45 activity in T cells from disease controls (DSC) was not
significantly different from HC. Both reduced glutathione (GSH) ( p< 0.001) and oxidized glutathione (GSSG)
( p< 0.05) were significantly lower in RA PB T cells compared with HC PB T cells. Treatment of RA PB T cells with
the GSH precursor N-acetyl cysteine increased CD45 phosphatase activity and proliferation, while it decreased Lck
kinase phosphorylation, which is regulated by CD45. Our observations lead to the hypothesis that the largely
reversible oxidative inactivation of the CD45 phosphatase may underlie the decreased signaling efficiency and
functional responsiveness which are characteristic of RA PB CD4+ T cells. Antioxid. Redox Signal. 19, 2280–2285.
Introduction
Rheumatoid arthritis (RA), a common autoimmunedisease that affects synovial joints, is associated with
dysfunctional immune regulation. Cells from the peripheral
blood (PB) and synovial fluid (SF) of RA patients are hypo-
responsive with attenuation in the T-cell-antigen-receptor
(TCR) signaling pathway (1, 2). The magnitude of the calcium
(Ca2 + ) flux induced by TCR engagement in RA CD4 + T cells
is decreased (1), and upstream changes such as in CD3f and
linker for activation of T cells (LAT)may explain this effect (2).
The fact that TCR signaling is important in the development
of arthritis has been shown in mice in which a spontaneous
mutation of ZAP-70, which transduces signals from the TCR,
gave rise to chronic inflammatory arthritis (6). These obser-
vations suggest that changes in any one of a number of
components involved in regulating TCR signaling may pro-
mote RA by altering signaling thresholds in lymphocytes.
In RA patients, reactive oxygen intermediates (ROI) are
abundant in the SF and PB, and glutathione (GSH) antioxi-
dant protectionwithin cellsmay be impaired (2). Thismay not
only result from the inflammatory processes, but it could also
result from dietary insufficiency in antioxidant vitamin C,
which has been linked to the occurrence of inflammatory ar-
thritis (3). Cigarette smoking, which also depletes blood levels
of reduced GSH, is also an important risk factor for RA. The
Innovation
We have described an acquired signaling dysfunction in
chronic inflammatory arthritis that occurs through oxida-
tive inactivation of the CD45 phosphatase. This dysfunction
may substitute for or reinforce genetically determined im-
mune aberrations that may together initiate and perpetuate
chronic inflammatory disease. Oxidative stress and immune
cell dysfunction are two long-recognized features of rheu-
matoid arthritis. We have provided a novel mechanism, the
oxidative inactivation of CD45, that unifies these features
and provides a rationale for new therapies of chronic in-
flammatory arthritis through antioxidant supplementation.
Rheumatology Research Group, Centre for Translational Inflammation Research, College of Medical and Dental Sciences, School of
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altered redox state in RA may promote alterations in TCR
signaling in RA (2), a process that may involve displacement
of LAT from themembrane. The protein tyrosine phosphatase
(PTP) CD45, which is the most abundant PTP in leucocytes,
regulates the very first stages of the TCR signaling cascade
and, in systemic lupus erythematosus patients (9), its activity
is decreased, probably because of the sensitivity to oxidation
of the cysteine at the active site of all PTPs (7). Given this, we
set out to investigate the activity of CD45 phosphatase in RAT
cells and to relate this to both the redox status of the cells and
their functional responses.
Proliferation Responses of RA PB T Cells Are Decreased
RA PB CD4 + T cells display a reduction in the response of
the cells to activation through the TCR (1), and so, we initially
set out to confirm these findings in the RA patients investi-
gated in this study (PB taken from seven patients in Table 1).
After stimulation with anti-CD3/anti-CD28, there was a sig-
nificant reduction in the proliferation of the cells from the RA
patients compared with the HC (Fig. 1A).
CD45 phosphatase activity is decreased in RA
but not in disease control patients
Phosphatase activity of CD45 was then assessed in
both RA PB and RA SF, and this was compared with that of
HC PB CD4 + T cells (Fig. 1B). The CD45 activity in RA CD4 +
T cells was 56% lower in PB (0.19 – 0.03 lmoles/lg/h;
mean – SEM CD45 activity; p< 0.02) and 59% lower in
SF (0.18 – 0.04 lmoles/lg/h; mean – SEM CD45 activity;
p < 0.05) than in HC (0.43 – 0.05 lmoles/lg/h; mean– SEM
CD45 activity). This was restricted to RA patients, as there
was no significant difference in the activity of CD45 from the
PB (0.40 – 0.05 lmoles/lg/h; mean– SEM CD45 activity) and
SF (0.35 – 0.03 lmoles/lg/h; mean– SEM CD45 activity)
CD4 + T cells of disease control (DSC) patients (Fig. 1, last two
columns). Furthermore, the CD45 from the DSC PB and SF
CD4 + T cells was significantly more active than the RA PB
and SF CD4 + T cell CD45 (PB p < 0.02 and SF p< 0.05). Our
observation that the phosphatase activity of CD45 isolated
from RA PB and SF CD4+ T cells is decreased, when com-
pared with HC PB CD4+ T cells, may lead to changes in the
activity of Src kinases and in downstream calcium signaling.
Interestingly, this decreased activity was restricted to RA
patients, which is consistent with previous studies in which
calcium signaling depression was not seen in DSC groups
comprising just ankylosing spondylitis and osteoarthritis
patients (1). The absence of any significant change in CD45
activity in the rheumatoid factor sero-negative DSC group
suggests that inflammation alone is not the sole cause of the
changes we have seen in RA.
Antioxidant defense mechanisms of RA CD4+
T cells and fluids are depressed
Levels of both GSH and oxidized glutathione (GSSG) were
significantly lower in both the RA serum and the RAPBCD4 +
T cells than in their matched HC serum and PB CD4 + T cells
(Fig. 2A, B). SF CD4+ T cell levels of GSH were even lower
than both HCCD4 + T cell and RA PB CD4 + T cell levels. GSH
in CD4 + T cells from DSC patients was not significantly dif-
ferent from either the HC or RA samples. DSC GSH was
clearly closer to HC levels (HC PB 10.28– 1.90; DSC PB
9.276– 1.46; RA PB 6.64 – 1.42 lM). The DSC PB CD4+ T cell
samples showed no difference in their reduction capacity
compared with HC samples but were significantly higher
than RA PB CD4 + T cells. Despite this, RA patients main-
tained reduction potentials, (dependent on GSH and GSSG
concentrations), at levels similar to those in HC, demonstrat-
ing the maintenance of the normal redox environment, which
is vital for cell function and survival (8). The reduction po-
tentials observed in the PB CD4+ T cells of all groups (Fig. 2)
are in the normal range, and so, this suggests that their sur-
vival is not compromised by redox stress. However, the de-
creased reduction capacity in RA PB CD4 + T cells suggests
that they are less able to withstand the effects of ROI, thus
allowing the oxidative inactivation of the CD45 phosphatase.
Boosting reduction capacity in vitro enhances RA T cell
function, CD45 phosphatase activity and decreases
Lck phosphorylation
Incubation with N-acetyl cysteine (NAC) (100 lM) for 2 h
before stimulation significantly increased RA PB CD4 + T cell
responses compared with untreated cells from the same pa-
tient (Fig. 3A, last two columns). The proliferative responses of
the RA preincubated cells were almost equivalent to those of
HC cells not treated with NAC (Fig. 3A, first column).
We also measured the relative increase in CD45 phospha-
tase activity after pre-treatment of RA PB CD4+ T cells
and matched HC samples with NAC (Fig. 3B). The increase
was significantly greater ( p < 0.05) in RA PB CD4 + T cell
samples (35.8 [14–74]%; median [range]) than that observed
with HC PB CD4+ T cells (12.6 [5–70]%; median [range]). The
increase in CD45 activity in RA cells correlated with the
Table 1. Rheumatoid Arthritis and Disease Control Patient Details
RA patients
(proliferation) (n = 7)
RA patients (CD45 and GSH)
(n = 11)
DSC patients
(n = 8)
Age, mean (range) 58.9 (32–81) 60 (32–79) 52.6 (18–72)
Sex, females/males 7/0 8/3 5/3
Disease duration, mean (range), years 20.3 (4–50) 11.7 (0.4–28) 5.5 (0.4–10)
ESR, mean (SD) (mm/h) 47.7 (31.4) 52.9 (20.3) 44.2 (20.9)
CRP, mean (SD) (mg/ml) 63.7 (74.0) 83.4 (36.6) 31.2 (26.1)
Seven sero-positive RA patient samples were used for proliferation responses and CD45 enhancement assays using N-acetyl cysteine.
Eleven sero-positive RA samples and 8 DSC were used for CD45-specific activity and GSHmeasurements. All assays on patient samples were
done in parallel with an age- and sex-matched HC sample.
RA, rheumatoid arthritis; DSC, disease control; GSH, glutathione; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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increase in proliferative responses at 1.0 lg/ml anti-CD3
( p< 0.02) (Fig. 3C).
Dephosphorylation of Lck Tyr 505 by CD45 is a priming
event in the activation of Lck and subsequent events in
downstream TCR signaling. We assessed the levels of Lck
phospho-Tyr 505 in cells preincubated with NAC and then
activated by cross-linking CD3. In resting cells (Fig. 4 top
panels), NAC caused the decrease in the level of phospho Lck
as the concentration of NAC increased. In activated cells (Fig.
4 bottom panels), levels of phospho-Lck were higher, particu-
larly in the cells not incubated with NAC. However, as the
concentration of NAC increased a distinct population of Lck
phospho negative cells appeared. Given that the phosphory-
lation of tyrosine 505 is tightly regulated by CD45, this dem-
onstrates that the decreased activity of CD45 phosphatase that
we have observed in the RApatients (Fig. 1) results in the poor
proliferation and responses of the cells (Fig. 3) through altered
regulation of Lck phosphorylation.
Since CD45 activity was enhanced by NAC in the RA pa-
tients, it suggests that the inactivation was due to a partially
reversible oxidation of the CD45 phosphatase active site.
However, CD45 phosphatase activity in RA PB CD4 + T cells
was not fully restored to the level in HC by NAC (data not
shown), suggesting that a degree of irreversible modification
may also have occurred. Recent structural studies on the ox-
idation of PTPs show that the formation of a sulfenyl-amide
linkage is the first step in the oxidation (7). While this inacti-
vates the enzyme, it may also protect against further irre-
versible oxidation to sulfinic and sulfonic forms, and so may
explain why much of the oxidation observed was reversible.
Enhanced proliferation correlated with the increase in CD45
phosphatase activity, demonstrating that the function of RA
PB CD4+ T cells can be significantly enhanced by NAC to a
near normal response.
There is considerable evidence of oxidative damage
occurring both locally and systemically in RA (2), and so,
we suggest that in this environment a decreased CD45
phosphatase activity results due to oxidation. Chronic
exposure of blood to what may be generally low levels of
oxidants, associated with hypoxic reperfusion injury and
systemic inflammation, would mean that the antioxidant
defenses will be continually attacked and depleted. This
decreased reduction capacity may be particularly impor-
tant for T cells, which are long-lived. A similar chronic
accumulation of oxidative damage may occur in aging. We
have demonstrated that CD45 phosphatase activity is de-
creased in T cells from healthy elderly individuals (4), and
the accumulation of oxidative damage in elderly people is
known to correlate with a decrease in the plasma GSH
levels.
In TCR signaling, the importance of CD45 in controlling
early events means that inhibition of its action will supersede
any other signaling changes. The potential importance of
these early TCR signaling events for the etiology of arthritis
was demonstrated in a mutant mouse model (6) in which a
point mutation in the TCR-proximal ZAP-70 protein leads to
an attenuated CD4 T cell TCR signal, very similar to what we
have observed in RApatients. In these animals, a spontaneous
persistent arthritis ensued that could be prevented by re-
introducing a fully functional ZAP-70 molecule. While in this
model thymic selection of autoreactive T cells was shown to
occur, the reasons for the development of arthritis remain
unclear. However, it suggests that the acquired dysregulation
of TCR proximal signaling which we have observed has the
potential to allow aberrant autoimmune responses to occur,
perhaps by interfering with the regulation of peripheral tol-
erance, giving rise to a persistent inflammatory arthritis. Low
A
B
FIG. 1. Proliferation and CD45 phosphatase activity in
CD41 T cells from rheumatoid arthritis (RA) patients is
depressed compared with healthy controls (HCs). (A) CD4+
T cells isolated from HC peripheral blood (PB), or from RA PB
were resuspended in complete medium. 1· 105 cells/well
were then stimulated using immobilized anti-CD3 (0.5, 1.0, or
2.0lg/ml) and CD28 (2lg/ml) in a 96-well plate for 48h.
0.3lCi of 3H-thymidine was then added and 24h later, DNA
was harvested. The data presented earlier represent the mean
of seven separate patients and controls (– SEM) with triplicate
readings for each sample. +p< 0.02, using the Wilcoxon
matched-pair nonparametric analysis. (B) CD4+ cells isolated
from the PB (n= 11) and synovial fluid (SF) (n= 6) of RA pa-
tients (Table 1) and PB (n= 8) and SF (n= 5) DSC (Table 1)
were lysed, and the specific activity of CD45 was measured in
the cells as described in the ‘‘Materials and Methods’’ section.
This was compared with age- and sex-matched HC (n= 19)
isolated at the same time. The results are the mean of at least
duplicate readings for each patient or control; the bar shows
the median value. p< 0.05 (+), p<0.002 (++) as determined
by the Wilcoxon matched-pair nonparametric analysis.
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FIG. 2. Concentration of glutathione (GSH) is decreased
in RA patients, but the reduction potential is normal. The
concentration of (A) GSH and (B) oxidized glutathione
(GSSG) was measured in lysates from CD4 + T cells isolated
from HC PB and RA PB and SF (n= 11) and DSC PB (n = 8).
The figures for cellular concentrations represent the GSH/
GSSG from 0.5 · 106 cells diluted in 0.5ml of lysis buffer.
Levels in serum and SF were also measured. The Wilcoxon
matched-pair nonparametric analysis was used to analyze
the results. p< 0.05 (+), p< 0.0002 (++), p< 0.001 (A),
p < 0.005 (). (C) Reduction potential (in mV) was deter-
mined using the Nernst equation set out in the ‘‘Materials
and Methods’’ section. There were no significant differences
between the patient and control samples.
A
B
C
FIG. 3. Proliferation responses and CD45 activity of RA PB
CD41 T cells can be enhanced by incubation with N-acetyl
cysteine (NAC). (A) CD4+ T cells isolated from HC PB were
resuspended in complete medium plated at 1·105 cells/well
and then stimulated using immobilized anti-CD3 (1.0lg/ml)
and CD28 (2lg/ml) in a 96-well plate for 48h before receiving
0.375lCi of 3H-thymidine per well and harvesting at 72h.
CD4+ T cells from RA PBwere preincubated for 2h in complete
medium or complete medium supplemented with 100lM
NAC before being washed ·2 in complete medium and stim-
ulated. Data are mean (–SEM) of triplicates. +p<0.02. (B) HC
PB and RA PB CD4+ T cells treated at the same time as the cells
used in the proliferation assays in A were lysed, and CD45
phosphatase activity was measured. The graph shows the
percentage increase in CD45 phosphatase activity of the NAC
treated cells compared with their untreated counterparts.
+p<0.02. (C) Shows the correlation between increase in CD45
phosphatase activity and the increase in proliferation response
above untreated samples in RA patients. Correlation was de-
termined using the Spearman’s nonparametric test (r=0.893).
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dietary intake of vitamin C (the other major anti-oxidant, in
equilibrium with GSH) has been related to the occurrence of
polyarthritis (3). Such alterations in the systemic redox bal-
ance could enable inactivation of CD45, thus allowing aber-
rant immune function and initiation and/or perpetuation of
inflammatory arthritis.
Notes
Materials and methods
RA and DSC patients. PB was obtained from arthritis
patients undergoing treatment in the clinics of the Rheu-
matology Department of Selly Oak, or City Hospitals, Bir-
mingham (n = 18). SFs were collected when available from
patients undergoing therapeutic aspirations of knee joints.
All RA patients satisfied the 1987 American College of Rheu-
matology (ACR)criteria forRA.PB(andSFwhenavailable)was
also taken from arthritis patients not meeting the 1987 ACR
criteria for RA (n= 8) (Gout; reactive arthritis; psoriatic arthritis;
sero-negative arthritis; osteoarthritis). These formed the disease
control patient group (DSC). All samples were obtained under
the approval of South Birmingham and Sandwell & West Bir-
mingham Hospitals Local Research Ethics Committees. All
patient samples werematchedwith a PB sample collected from
age- and sex-matchedhealthycontrol (HC) staffmembersof the
University of Birmingham (n= 26, mean age of controls=49.42,
range 26–54, mean age of patients= 57.42, range 18–81) (see
Table 1).
Lymphocyte isolation from PB and SF. PB and SF were
collected into preservative-free heparin, and CD4 + T cells
were isolated by Ficoll–Paque (Amersham Biosciences) den-
sity gradient centrifugation and magnetic bead separation.
Incubation of CD4+ T cells with NAC. Purified cells were
incubated for 2 h with andwithout NAC (100lM) (found to be
the optimal concentration for restoring PTP activity—data not
shown) in complete medium and were then stimulated as de-
scribed earlier or used in the assay for CD45 activity (below).
Measurement of CD45 phosphatase activity. CD45
phosphatase specific activity was measured using an anti-
body capture technique as previously described (5).
Measurement of GSH. Purified CD4+ T cells (5 · 105)
were lysed and de-proteinated in 1.8% perchloric acid. Fresh
serum and SF were similarly treated and stored at - 80C.
10mM dithio-bis (2-nitrobenzoic acid), 0.5mM HCl, 0.075U
GSH reductase, and 1mM NADPH were added to triplicate
samples, and the change in absorbance at 412 nm over 15min
at 37C was measured and compared with a GSSG standard
curve. GSSG was then determined by subtracting the amount
of GSH from the total GSH concentration. GSHwasmeasured
similarly but in the absence of GSH reductase and NADPH.
Proliferation assays. 105 cells CD4 + T cells were acti-
vated with anti-CD3 (1lg/ml) and anti-CD28 (2 lg/ml) im-
mobilized onto 96-well plates using goat anti-mouse IgG
(100 ng/ml). After 48 h, 3H-thymidine was added, and cells
were harvested at 72 h for counting using an LKB Betaplate
reader (LKB-Wallac).
Flow cytometry of phospho-lck. Peripheral blood mono-
nuclear cells (0.5 · 106) were plated onto 24-well plates in
medium (RPMI 1640 with 10% fetal calf serum and gps)
(2mls) with and without a range of concentrations of NAC.
After 2 h of incubation at 37C, cells were rapidly cooled on
FIG. 4. Phosphorylation of-Lck on tyrosine 505 is decreased after activation and incubation of RA PB CD41 T cells with
NAC. Peripheral blood mononuclear cells from RA patients were incubated with 0, 10,100, and 1000lmol NAC for 2 h,
cooled, and then activated using anti-CD3 antibody. After 60 s, cells were fixed, permeabilized, and stained for CD4 and
phosphotyrosine 505 Lck. The top four panels show unstimulated cells, and the bottom panel shows cells activated with anti-
CD3. The numbers show the percentage of cells in each quadrant. The analysis was repeated with three different patients, and
the representative result from one patient is shown.
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ice, sedimented, and then stimulated at 37C using pre-
warmed anti-CD3 (Immunotools) and goat anti-mouse IgG
(Sigma) to cross-link receptors. One minute after cross-
linking, cells were fixed by the addition of three volumes of
Phosflow Fix buffer (BD). This was left for 15min at 37C,
and then, the cells were permeabilized using Phosflow
perm/wash buffer (BD) to check for the presence of phos-
phorylated tyrosine residue 505 of Lck (BD LcK [Y505] PE)
and CD4 (anti-CD4 APC Immunotools), and they were then
analyzed by flow cytometry using a Coulter Cyan flow cyt-
ometer. Parallel samples with appropriate isotype controls
were also analyzed.
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